In recent years, the understanding about the different clinical phenotypes, diagnostic and
prognostic factors of myelin oligodendrocyte glycoprotein-antibody-associated disorders …

Pediatric-onset multiple sclerosis (POMS) is a rare neuroinflammatory and
neurodegenerative disease that has a significant impact on long-term physical and cognitive …

The field of acquired CNS neuroimmune demyelination in children is transforming. Progress
in assay development, refinement of diagnostic criteria, increased biological insights …

The current diagnostic criteria for pediatric onset multiple sclerosis (POMS) are summarized,
as well as the evidence for performance of the most recent iteration of McDonald criteria in …

Background Ocrelizumab is a recombinant humanized anti-CD20 monoclonal IgG1,
approved by FDA and EMA for adult patients with multiple sclerosis (MS). The data on the …

Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational
studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) …

Multiple sclerosis (MS) is the most common autoimmune, chronic inflammatory
demyelinating disorder of the central nervous system. Pediatric-onset MS (POMS), as …

Background and purpose Rituximab (RTX) is frequently used off‐label in multiple sclerosis.
However, studies on the risk–benefit profile of RTX in pediatric‐onset multiple sclerosis are …

Significant progress has been made in the field of pediatric neuroimmunology over the past
few years. With the detection of conformationally correct myelin oligodendrocyte …

Juvenile multiple sclerosis (JMS) is a rare but significant subtype of multiple sclerosis (MS)
that affects a small percentage of patients under the age of 10 and 3–5% of all MS patients …